5-(3-methylphenoxy)-2(1h)-pyrimidinone has been researched along with pyrimidinones in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Handler, JA; Lipinski, CA; Ochman, AR; Reaume, AG; Saporito, MS | 2 |
| Ciallella, JR; Reaume, AG | 1 |
| Block, B; Cha, BS; Chung, CH; Frias, JP; Greenway, F; Kim, BJ; Kim, SG; Lee, MK; Lee, SH; Moon, MK; Park, HK; Rhee, SY; Watkins, E | 1 |
| Lipinski, CA; Reaume, AG | 1 |
2 review(s) available for 5-(3-methylphenoxy)-2(1h)-pyrimidinone and pyrimidinones
| Article | Year |
|---|---|
In vivo phenotypic screening: clinical proof of concept for a drug repositioning approach.
Topics: Diabetes Mellitus, Type 2; Drug Discovery; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Humans; Pyrimidinones | 2017 |
High throughput in vivo phenotypic screening for drug repurposing: Discovery of MLR-1023 a novel insulin sensitizer and novel Lyn kinase activator with clinical proof of concept.
Topics: Drug Discovery; Drug Repositioning; High-Throughput Screening Assays; Humans; Hypoglycemic Agents; Insulin; Phenotype; Pyrimidinones; src-Family Kinases | 2020 |
1 trial(s) available for 5-(3-methylphenoxy)-2(1h)-pyrimidinone and pyrimidinones
| Article | Year |
|---|---|
A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; PPAR gamma; Pyrimidinones; src-Family Kinases; Treatment Outcome; Young Adult | 2020 |
2 other study(ies) available for 5-(3-methylphenoxy)-2(1h)-pyrimidinone and pyrimidinones
| Article | Year |
|---|---|
The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Homeostasis; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Mice; Mice, Inbred ICR; Pyrimidinones; Rats; Receptor, Insulin; src-Family Kinases | 2012 |
MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo.
Topics: Adenosine Triphosphate; Allosteric Regulation; alpha-Glucosidases; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Mice; Mice, Inbred ICR; Mice, Knockout; Peroxisome Proliferator-Activated Receptors; Protein Kinase Inhibitors; Pyrimidinones; Receptors, Glucagon; Signal Transduction; src-Family Kinases | 2012 |